Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcoma

被引:45
作者
Amant, F
Schurmans, K
Steenkiste, E
Verbist, L
Abeler, VM
Tulunay, G
de Jonge, E
Massuger, L
Moerman, P
Vergote, I
机构
[1] Katholieke Univ Leuven Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, B-3000 Louvain, Belgium
[2] Katholieke Univ Leuven Hosp, Dept Pathol, B-3000 Louvain, Belgium
[3] Norwegian Radium Hosp, Dept Pathol, Oslo, Norway
[4] SSK Ankara Matern & Womens Hosp, Dept Gynecol Oncol, Ankara, Turkey
[5] Ziekenhuis Oost Limburg, Dept Obstet & Gynecol, Genk, Belgium
[6] Univ Nijmegen Hosp, Dept Obstet & Gynecol, NL-6500 HB Nijmegen, Netherlands
关键词
adenosarcoma; immunohistochemistry; estrogen; progesterone; treatment; uterus;
D O I
10.1016/j.ygyno.2004.03.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Given the paucity of data regarding hormone dependency, it was the purpose of this study to screen for the presence of estrogen and progesterone receptors in uterine adenosarcoma (UAS). Methods. One hundred and five centers were asked to screen their files for uterine adenosarcomas. A immunohistochemical estrogen and progesterone receptor determination was performed. Results. Twenty-eight primary UAS were stained, including one cervical adenosarcoma. Sarcomatous overgrowth could be observed in eight. Furthermore, two cases of recurrent UAS, one only consisting of endometrial stromal sarcoma, were stained. UAS lacking sarcomatous overgrowth showed estrogen receptor positivity in 17/20 (85%) and 16/20 (80%) in the epithelial and sarcomatous component, respectively. Progesterone positivity was observed in 13/20 (65%) and 12/20 (60%) in the epithelial and sarcomatous component, respectively. In 18/20 (90%) of the cases, either the estrogen or the progesterone receptor stained positive in the sarcomatous component. UAS with sarcomatous overgrowth showed estrogen receptor positivity in 4/8 (50%) and 0/8 (0%) in the epithelial and sarcomatous component, respectively. Progesterone positivity was observed in 2/8 (25%) and 1/8 (12%) in the epithelial and sarcomatous component, respectively. The stromal component of both recurrent cases stained moderately positive for estrogen receptor whereas progesterone receptor was considered negative. Conclusion. The observation that the sarcomatous component of UAS without sarcomatous overgrowth frequently expresses hormone receptors might be of significant clinical importance. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:680 / 685
页数:6
相关论文
共 42 条
[1]   Immunohistochemical determination of hormone receptors in uterine adenosarcomas [J].
Amant, F ;
Gabriel, C ;
Moerman, P ;
Vergote, I .
GYNECOLOGIC ONCOLOGY, 2003, 88 (03) :463-464
[2]   The diagnostic problem of endometrial stromal sarcoma: report on six cases [J].
Amant, F ;
Moerman, P ;
Cadron, I ;
Neven, P ;
Berteloot, P ;
Vergote, I .
GYNECOLOGIC ONCOLOGY, 2003, 90 (01) :37-43
[3]  
BAKER VV, 1984, OBSTET GYNECOL, V63, pS72
[4]  
Blom R, 1999, INT J GYNECOL CANCER, V9, P37
[5]   UTERINE MULLERIAN ADENOSARCOMA FOLLOWING ADENOMYOMA IN A WOMAN ON TAMOXIFEN THERAPY [J].
BOCKLAGE, T ;
LEE, KR ;
BELINSON, JL .
GYNECOLOGIC ONCOLOGY, 1992, 44 (01) :104-109
[6]   PRIMARY UTERINE ENDOMETRIAL STROMAL NEOPLASMS - A CLINICOPATHOLOGICAL STUDY OF 117 CASES [J].
CHANG, KL ;
CRABTREE, GS ;
LIMTAN, SK ;
KEMPSON, RL ;
HENDRICKSON, MR .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1990, 14 (05) :415-438
[7]   Low-grade endometrial stromal sarcoma: hormonal aspects [J].
Chu, MC ;
Mor, G ;
Lim, CY ;
Zheng, WX ;
Parkash, V ;
Schwartz, PE .
GYNECOLOGIC ONCOLOGY, 2003, 90 (01) :170-176
[8]   MULLERIAN ADENOSARCOMAS OF THE UTERUS WITH SARCOMATOUS OVERGROWTH - A CLINICOPATHOLOGICAL ANALYSIS OF 10 CASES [J].
CLEMENT, PB .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1989, 13 (01) :28-38
[9]  
CLEMENT PB, 1974, CANCER-AM CANCER SOC, V34, P1138, DOI 10.1002/1097-0142(197410)34:4<1138::AID-CNCR2820340425>3.0.CO
[10]  
2-9